In commercial broiler and swine units, water-medication systems operate by continuous injection of a water-miscible veterinary API concentrate into the drinking line at a preset proportion. The final working solution is typically prepared by dilution of a 200 g/L active concentrate at ratios between 1:1000 and 1:200, yielding final API concentrations from 100 mg/L to 1,000 mg/L; the selected ratio derives from the target therapeutic dose of 10–20 mg/kg bodyweight/day and observed water consumption of 100–200 mL/kg/day. Water quality is the first process variable to be fixed, because total hardness above 300 mg/L CaCO₃ measured by ISO 6059:1984 can reduce solubility of acidic or carboxylate-containing actives and produce insoluble carbonate deposits inside float-operated proportioners. Where line pH exceeds 7.5, a stock solution shroud using 0.1% v/v orthophosphoric acid is flushed through the proportioner and static mixer before and after each dosing cycle to minimise precipitation at the injection point. Microbial quality of the final medicated water during the administration period should comply with Ph. Eur. 5.1.4 limits for non-sterile aqueous preparations, and the water source should be validated according to USP <1231> for total organic carbon and conductivity. Downstream production equipment includes high-density polyethylene stock tanks, diaphragm or peristaltic dosing pumps calibrated by timed volumetric delivery over 5 min against a Class A graduated cylinder, in-line static mixers, and opaque UV-stable flexible lines; pump flow drift exceeding ±5% at stock solution viscosity above 15 mPa·s is a known batch failure mode. Terminal finished forms include oral medicated drinking water concentrate, proportioner-ready stock solutions, and farm-use drinking water medication in 20 L to 200 L containers.

Why Does Dissolved Oxygen in Water for Injection Accelerate API Solution Degradation During Autoclaving?

For sterile veterinary injectables, the decision to terminal sterilise or aseptically filter the final product is determined before filling line specification. Aqueous API solutions are commonly compounded at 10–40% v/v of the bulk liquid concentrate with Water for Injection q.s. to the batch volume; tonicity is adjusted with sodium chloride to 280–320 mOsmol/L, and pH is corrected with 1 N hydrochloric acid or sodium hydroxide to the active molecule’s maximum kinetic stability range. The filled solution must meet Ph. Eur. 2.6.1 sterility, Ph. Eur. 2.6.14 bacterial endotoxins with a kinetic chromogenic LAL method, and USP <85> endotoxin limits consistent with the calculated maximum bolus dose per kg bodyweight. Processing equipment includes a compounding vessel with bottom-mounted magnetic stir bar, 0.45 µm polypropylene clarification filter, 0.22 µm PVDF sterilizing-grade filter, and a Grade A unidirectional airflow filling station certified to ISO 14644-1 Class 5. Glass vials are washed, sterilised, and depyrogenated at 250 °C for 30 min in a dry-heat tunnel; rubber stoppers are rinsed in WFI and autoclaved. Dissolved oxygen in the compounded solution is measured by a polarographic sensor, and when the reading exceeds 2.0 mg/L before autoclaving, nitrogen sparging is introduced through a 0.22 µm point-of-use filter at 0.5–1.0 bar until the oxygen level declines below 0.5 mg/L. Terminal sterilisation at 121 °C for 15 min is selected only when a forced degradation study confirms assay loss below 2.0% and pH drift below 0.2 units; otherwise, aseptic filtration is mandated under EU GMP Annex 1 and 21 CFR 210/211 for heat-labile formulations. Terminal finished products include single-dose 100 mL and 250 mL vials, multi-dose 500 mL infusion containers, and companion animal injectable solutions for intravenous or subcutaneous administration.

Medicated Feed Premix Homogeneity and Carryover Control Under Regulation (EU) 2019/4

When the liquid veterinary API concentrate is introduced into medicated feed premix, the critical process objective is a homogeneity coefficient of variation below 5% across 10 sampling points after final mixing and a carryover of active substance into the subsequent non-target batch below <1% of the previous batch concentration, as required for prescribed medicated feed under Regulation (EU) 2019/4. The liquid API solution is sprayed onto a porous carrier—usually ground corn cob, silica, or lactose—through a spray bar at 2–4 bar atomising air pressure; the addition ratio is typically 0.5–2.5% w/w of the premix mass, while the final feed incorporation rate ranges from 0.5–5.0 kg of premix per metric tonne of finished feed depending on veterinary prescription. The carrier is dried to moisture below 2.0% w/w before spraying, and residual moisture after spraying is controlled below 5.0% w/w according to ISO 6496:1999. Mixing is performed in a twin-ribbon vertical mixer or paddle mixer with a minimum mixing time established from a mixing curve; sampling follows ISO 6497:2002, and assay of the active in premix and finished feed is performed by HPLC-UV using a method validated under VICH GL1. When the premix is subsequently pelleted through a ring-die pellet mill with conditioning temperatures of 75–85 °C for 20–30 s, a thermolabile API solution may lose 5–15% of assay, so the die temperature and post-pellet cooling must be monitored and the cooling air adjusted to bring pellet temperature to no more than 5 °C above ambient before bagging. Terminal finished products include medicated meal feed, pelleted feed, and top-dress premix in 20 kg or 25 kg valve bags.

Prior to dry blending in a high-shear pharmaceutical mixer, the liquid API concentrate is adsorbed onto a porous carrier composed of lactose monohydrate, pregelatinized starch, and colloidal silicon dioxide at a ratio of 1:0.4:0.05 w/w to convert the solution into a free-flowing granulation substrate. The liquid addition ratio during wet granulation is held between 3% and 8% v/w of the dry powder charge, and the final oral powder or granule blend contains 10–25% w/w of the API-loaded carrier; individual sachet fills range from 2 g to 20 g for piglets, calves, and companion species. Compliance for the non-sterile oral powder is governed by Ph. Eur. 5.1.4 for microbiological quality, with total aerobic microbial count not exceeding 10³ CFU/g and absence of Escherichia coli in 1 g, while particle size distribution is measured according to Ph. Eur. 2.9.38 analytical sieving and 21 CFR 211.65 equipment construction requirements. Downstream manufacturing runs through a high-shear granulator equipped with an impeller speed of 150 rpm and a chopper speed of 3000 rpm, wet massing time of 1–3 min, and transfer to a fluid-bed dryer with inlet air at 55–65 °C until loss on drying falls below 2.0% w/w. The dried granules are screened through a 0.8 mm sieve and final-blended in a Y-cone or V-blender; when relative humidity exceeds 60%, pre-drying of lactose and starch carriers is required because hygroscopic moisture uptake above 2.5% causes sieve blinding, caking, and inconsistent sachet fill weights. Terminal finished products include oral soluble powder sachets, milk-replacer powders, and direct-top-dress granules for administration onto feed.

When API Solution Replaces Dry Granulation Binders in Wet Granulation for Tablet Compaction

Wet granulation for veterinary tablets and boluses using the liquid API concentrate as part of the binder phase introduces a process window defined by granule moisture, compression force, and magnesium stearate lubricant. The granulation fluid is prepared by mixing 10–40% v/v API solution with purified water containing 5% w/w povidone K30 as binder; this liquid is added to a lactose-monohydrate and microcrystalline cellulose blend over 3–5 min until a final granule moisture of 2.5–3.5% w/w is reached. Tablet compression is performed on a rotary press with 18 mm concave tooling and compression force between 8 kN and 20 kN, targeting core hardness of 50–100 N by Ph. Eur. 2.9.8, friability below 1.0% by Ph. Eur. 2.9.7, disintegration time below 15 min by Ph. Eur. 2.9.1, and uniformity of dosage units according to Ph. Eur. 2.9.40. Capping and lamination are recurrent failure modes when granule moisture exceeds 3.5% or when magnesium stearate exceeds 2.0% w/w and shear mixing exceeds 5 min; sticking occurs when the tablet press turret speed exceeds 30 rpm without external lubrication. Compliance also requires dissolution testing according to Ph. Eur. 2.9.3 if a dissolution specification is stated in the veterinary marketing authorisation. The finished tablet dosage is commonly 100 mg, 250 mg, or 500 mg active per unit, and film coating is applied in a perforated pan with inlet air at 60–70 °C and pan speed 6–12 rpm. Terminal finished products include flavored companion-animal tablets, scored oral boluses for cattle, and film-coated tablets in blister packs.

Liquid-filled hard gelatin capsules are rejected when the fill matrix contains free water above 20% w/w because shell softening and pellicle cross-linking can occur before release; therefore the aqueous API solution is not directly filled into hard shells without prior adsorption or anhydrous co-solvent modification. For powder-filled veterinary capsules, the liquid API concentrate is sprayed into a wet granulation step at 15–25% w/w of the dry powder mass, and the resulting granules are dried to moisture below 3.0% w/w by Karl Fischer titration before encapsulation. Capsule filling is carried out on a dosator or dosing-disc machine with size 0 or 00 hard gelatin or HPMC shells; fill weight variation is controlled by Ph. Eur. 2.9.40 uniformity of dosage units, and disintegration is measured by Ph. Eur. 2.9.1. A 100% checkweighing step rejects units outside ±3% of target fill mass, and metal detection is set to isolate ferrous inclusions above 0.5 mm. Compliance for the capsule shell and fill formulation includes Ph. Eur. 5.1.4 microbiological criteria, and the filled capsules are packaged in PVC-aluminium blister packs with desiccant when the moisture barrier is insufficient. Published stability data for aqueous veterinary API solutions in liquid-filled hard capsules remains limited; direct liquid fill is therefore not recommended unless shell compatibility has been verified by dynamic vapour sorption at 40 °C/75% RH for 6 months. Terminal finished products include hard-shell companion-animal capsules, antibiotic and antiparasitic unit-dose capsules, and veterinary clinical trial capsule formulations.

Oral Drench Solution Viscosity, pH Drift, and Dosing Pump Calibration in Ruminant Administration

For oral drench solutions used in cattle and sheep, the liquid API concentrate is diluted into a palatable vehicle that typically contains 20–50% v/v API solution, 10% v/v propylene glycol or glycerol, preservative at a concentration validated by Ph. Eur. 5.1.3 antimicrobial preservation, and a viscosity-modifying agent such as hydroxyethylcellulose at 0.1–0.3% w/w. The final drench is administered at 5–20 mL per animal through a calibrated dosing hook or automatic drench gun; dosing pump calibration is performed gravimetrically over 10 discharges, with an acceptance limit of ±2% relative standard deviation. Viscosity is measured by a Brookfield viscometer at 20 °C and spindle speed 60 rpm, and values above 60 mPa·s cause orifice under-delivery and foaming during bottle filling. The mixing train includes a 316L stainless steel jacketed tank, a 100 µm in-line filter before the filling nozzle, and a high-density polyethylene container line purged with nitrogen if the API solution is oxygen-sensitive. pH is maintained within the product-specific stability range and monitored after storage at 25 °C/60% RH for 12 months according to the stability protocol; a pH drift greater than 0.5 units can indicate buffer depletion or hydrolytic degradation. Compliance for the non-sterile liquid product follows Ph. Eur. 5.1.4 and the relevant national registration dossier for veterinary oral liquids. Terminal finished products include 1 L and 5 L high-density polyethylene drench containers, hook-applicator bottles, and automatic drench gun cartridges.